SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is experiencing a significant surge due to a proposed merger with Applied Digital's cloud computing business, pivoting the company into ChronoScale, an AI-focused GPU compute platform. This strategic shift from medical exoskeletons to the high-demand artificial intelligence sector is driving community discussions around its low float, potential NVIDIA ties, and anticipated volatility, despite some concerns about substantial shareholder dilution.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X Shares

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is currently a focal point for investors, driven by the belief that ongoing global financial instability, extensive central bank liquidity measures, and concerns over currency strength will continue to underpin demand for gold. Community conversations emphasize escalating geopolitical tensions and expectations of policy adjustments from central banks, positioning junior gold miners as a prominent defensive asset. Traders are actively observing market dynamics for further catalysts, even amidst discussions of potential price consolidation.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending with investors assessing a mix of significant defense contract wins and a forecasted lead in aircraft orders over Airbus, signaling a potential operational shift. Despite this, recent geopolitical sanctions and an FAA investigation into an engine incident are driving community discussion around production quality and the company's path to recovery.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is generating significant conversation as its pivot to AI/HPC data centers fuels both strong bullish conviction and intense skepticism. While many tout its substantial power capacity, existing hyperscaler contracts, and rumors of further major partnerships as massive growth catalysts, others express deep concern over project execution risks and potential dilution. The community remains sharply divided on its long-term valuation amidst broader small-cap volatility and its perceived correlation to Bitcoin's price movements.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as the market anticipates potential government Plutonium awards and reflects on recent DOE safety approval for its Aurora fuel facility, placing it at the intersection of nuclear energy and AI data center demand. While bulls foresee significant growth fueled by this sector, bears heavily debate the valuation given the company's lack of revenue, ongoing share dilution, and notable insider selling.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Aptevo Therapeutics Inc

Aptevo Therapeutics is trending intensely due to its recent 1-for-18 reverse stock split, which has sparked widespread community concern over dilution and its financial trajectory. This comes amidst ongoing discussions of promising early clinical trial results for its mipletamig cancer drug, showcasing high remission rates for AML. Investors are sharply divided between deep skepticism over management's financial actions and bullish anticipation of a potential buyout or significant drug advancement.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing significant discussion and volatility as the community weighs the impact of the FDA's approval of Novo Nordisk's oral GLP-1 drug, alongside proposed legislation to restrict compounded versions of weight-loss medications. While many investors are expressing frustration over persistent declines and bearish sentiment, others view current price levels as a potential accumulation zone, anticipating a short squeeze, benefits from legitimate compounding, and growth from recent international expansions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is facing intense scrutiny as new political discussions, particularly related to recent Epstein file disclosures, fuel a "pump and dump" narrative among critics who highlight perceived risks. Conversely, supporters remain focused on the company's long-term potential, citing its strategic pivot towards "fusion" technology and the anticipated launch of related ETFs, leading to sharply divided sentiment surrounding its valuation.

Zoracles

Zoracles (ZORA) is actively discussed for its potential as a creator-focused protocol leveraging the Coinbase Base ecosystem for transforming digital content into tradable assets. The community sees current price action as an accumulation opportunity, anticipating significant long-term growth from ZORA's utility and broader crypto market catalysts.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is a major topic as the market anticipates upcoming Q4 delivery figures and a potential deadline for robotaxi advancements, sparking intense debate. While some hope for a catalyst from its AI and robotics vision, others express skepticism over slowing EV demand and the stock's elevated valuation amidst perceived "low volume pumps."

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average - Time to Sell?

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average - What's Next...

Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.4% - What's Next?

Arbutus Biopharma (NASDAQ:ABUS) Trading Down 6.4% - Time to Sell...

Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP

Two Seas Capital LP increased its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS - Free Report) by 10.3% during the 2nd quarter, according to its most recent Form 13F filing with...

Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital

Chardan Capital reiterated a "buy" rating and issued a $5.00 price target on shares of Arbutus Biopharma in a research report on Friday...

Arbutus Biopharma (NASDAQ:ABUS) Downgraded by Wall Street Zen to Hold

Wall Street Zen cut Arbutus Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday...

Arbutus Biopharma (NASDAQ:ABUS) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Arbutus Biopharma (NASDAQ:ABUS - Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus...

Are Medical Stocks Lagging  Arbutus Biopharma (ABUS) This Year?

Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?

Here is how Novartis (NVS) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?

Here is how Arbutus Biopharma (ABUS) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?

Here is how Aquestive Therapeutics (AQST) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Current Price	$4.72
Prev Close	$4.78
Open	$4.76
Dividend Yield	0.00%
50-Day Moving Average	$4.52
Beta	0.92
Avg. Volume	1.06M
PE Ratio	-21.28

52-Week High	$5.10
52-Week Low	$2.71
Market Capitalization	$919.31M
EPS (Annual)	-$0.3767
Price to Book	11.71
Revenue Per Employee	$140,250.00
Enterprise Value/EBITDA	N/A

ABUS
Arbutus Biopharma Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ABUS News

ABUSArbutus Biopharma Corp